key: cord-0722163-81dw1x1u authors: Puccioni-Sohler, Marzia; Poton, André Rodrigues; Franklin, Milena; da Silva, Samya Jezine; Brindeiro, Rodrigo; Tanuri, Amilcar title: Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19 date: 2022-02-25 journal: Revista da Sociedade Brasileira de Medicina Tropical DOI: 10.1590/0037-8682-0534-2021 sha: 94cb83d130d1e53cff14f96e6d2773c8b76767b0 doc_id: 722163 cord_uid: 81dw1x1u nan . Universidade Federal do Estado do Rio de Janeiro, Escola de Medicina e Cirurgia, Rio de Janeiro, RJ, Brasil. [2] . Universidade Federal do Rio de Janeiro, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Rio de Janeiro, RJ, Brasil. [3] . Universidade Federal do Rio de Janeiro, Instituto de Biologia, Rio de Janeiro, RJ, Brasil. We thank Dr. Josef Finsterer for the letter entitled "Pathophysiological aspects of neuro-COVID. Short title: Pathophysiology of neuro-COVID" and the interest in our publication (1) . The letter highlights how the neurological complications associated with COVID-19 can be widespread (1) . Dr. Finsterer cites three other pathophysiological mechanisms that can cause secondary neurological complications such as cardiac involvement, intensive care unit treatment, and neuroor myotoxicity of anti-COVID-19 drugs (2)- (7) . Although most of the references cited by the author were conducted prior to the COVID-19 pandemic and based on case reports, numerous other clinical conditions that can cause secondary damage to the nervous system exist. In addition to the letter, there are reports of acute kidney disease, septic shock, and liver and pancreatic dysfunction, among others (8)- (10) . Post-acute COVID-19 syndrome including cognitive decline has also been reported (11) , (12) . Neurotoxicity or myotoxicity of drugs used in the treatment of COVID-19 can occur in any other disease treated by any drug. Thus, these are drug reactions and not COVID-19 mechanisms. Our study aimed to introduce an issue that emerged within 7 months of the COVID-19 pandemic in 2020, the mechanisms of nervous system infection, and the absence of the virus in the cerebrospinal fluid (1) . These topics have widely been discussed in medical literature. We also highlighted the alarming epidemiological, clinical, and neurological findings reported for COVID-19 and the limitations in the laboratory diagnosis of neuro-COVID-19, considering the frequent negative SARS-CoV-2 real-time reverse transcription polymerase chain reaction test result in the cerebrospinal fluid. In conclusion, although our study was mainly focused on the emergence of a new neuroinvasive virus and its implications for neurological diagnosis, we agree that a broad study that would generate data on adverse reactions of drugs used in COVID-19 therapy as well as other secondary neurological complications would be of great importance. Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19 Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV Azithromycin-induced myasthenic crisis: reversibility with calcium gluconate An unusual complication of tocilizumab therapy: MRI appearances of thenar eminence pyomyositis Diagnostic work-up in steroid myopathy COVID-19 and central nervous system interplay: A big picture beyond clinical manifestation Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration Clinical management of COVID-19: living guidance Post-acute COVID-19 syndrome Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort